VolitionRx Limited (VNRX) Stock Forecast
VNRX analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 4.33 / 5 from 6 analysts
- Price target
- $13.62 average of analyst targets
- Upside to target
- +7,463.6% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.35
- 52-week range
- $0.18 – $8.98
VNRX analyst ratings
6 analystsNumber of analysts at each rating.
VNRX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
VNRX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.31 | −$0.31 | −$0.31 | −$1.06 | +70.7% | 1 |
| Current fiscal year (2026) | −$2.00 | −$2.00 | −$2.00 | −$4.40 | +54.5% | 1 |
| Next fiscal year (2027) | −$0.85 | −$0.85 | −$0.85 | −$2.00 | +57.5% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
VNRX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $696,150 | $462,000 | $1.2M | +11.0% | 5 |
| Current fiscal year (2026) | $2.7M | $2.3M | $3.5M | +57.7% | 5 |
| Next fiscal year (2027) | $9.3M | $3.5M | $21.3M | +240.5% | 4 |
VNRX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
VNRX revenue: reported and forecast
VNRX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.70 | −$0.58 | −$0.58 | −$0.58 | −$0.31 | −55.7% | 0 up · 0 down |
| Current fiscal year (2026) | −$2.60 | −$2.62 | −$2.62 | −$2.62 | −$2.00 | −23.1% | 1 up · 0 down |
| Next fiscal year (2027) | $10.80 | −$1.15 | −$1.15 | −$1.15 | −$0.85 | −107.9% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
VNRX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; VNRX beat in 6 of 12.
What analysts expect from VNRX
6 analysts cover VolitionRx; their consensus rating is buy (4.33 on a 1–5 scale, where 5 is a strong buy). The average price target is $13.62, 7,463.6% above the latest close of $0.18. Analysts expect earnings of −$2.00 per share for 2026, +54.5% from a year earlier. For 2027 the average estimate is −$0.85 per share on revenue of $9.3 million. VolitionRx beat the EPS estimate in 6 of the last 12 quarters.
Related: VNRX income statement, VNRX key metrics, VNRX chart. See the VNRX stock overview for the latest quote and news.
VNRX forecast FAQ
What is VolitionRx's price target?
The average analyst price target for VolitionRx is $13.62, 7,463.6% above the latest close of $0.18.
Is VolitionRx a buy, hold or sell?
Of 6 analysts covering VolitionRx, 3 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is VolitionRx's EPS forecast?
Analysts forecast −$2.00 per share for 2026 (range −$2.00 to −$2.00); for 2027 the estimate is −$0.85.
What is VolitionRx's revenue forecast?
The average revenue estimate for 2026 is $2.7 million, growth of 57.7%; for 2027 it is $9.3 million.
When does VolitionRx report earnings?
VolitionRx is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes; the EPS estimate is $-0.35.
Does VolitionRx usually beat earnings estimates?
VolitionRx reported EPS at or above the analyst estimate in 6 of the last 12 quarters.